Compare GSK plc (GSK) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard High Dividend Yield ETF — how do they compare? GSK plc trades at $50.4 (market cap $102.60B), while Vanguard High Dividend Yield ETF trades at $166.76. The key difference: GSK plc pays a 3.57% dividend while Vanguard High Dividend Yield ETF pays none, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | VYM | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | — |
52-Week High | $61.18 | $166.14 |
52-Week Low | $38.22 | $136.63 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
VYM trades at $166.51, up 0.27% with a bullish technical signal from moving averages but overbought RSI readings. The ETF recently hit a new 52-week high and maintains strong institutional interest despite some position reductions. Recent news highlights VYM's role in retirement income strategies with a 2.2% dividend yield and decade-long performance comparisons to the S&P 500.
The outlook remains positive for income-focused investors given VYM's sustainable dividend growth and sector diversification. Key risks include potential underperformance versus growth indices and sensitivity to interest rate changes. Wall Street sentiment is generally favorable with the ETF positioned as a core holding for retirement portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
